RECURSION PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.03 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.13, a 23.93% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.80, a 37.93% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.03, a 36.24% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.49, a 19.20% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.03, a 55.22% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $2.30, a 4.55% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.20, a 4.27% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $2.11, a 62.31% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.03 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $1.08 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $1.26 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $2.13 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $2.30 10-K · filed 2025-02-28 | |||
| 2024-09-30 | $2.53 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $2.71 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $2.80 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $2.20 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $2.19 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $2.18 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $2.03 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $2.11 10-K · filed 2023-02-27 | |||
| 2022-09-30 | $1.79 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $1.68 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $1.49 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $1.30 10-K · filed 2022-03-23 | |||
| 2021-09-30 | $1.22 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $1.18 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | $1.25 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |